GSK3B and leukemia: This is in line with published data showing that transient stabilization of MYC by inhibition of glycogen synthase kinase 3β (GSK-3β), which normally targets MYC for proteasomal degradation, sensitizes leukemia cells to chemotherapy leading to increased apoptotic cell death [52].